Antimicrobial Expert Advisory Group meeting 3 report

Thursday 4th June 2026, at 11am

Meeting held via MS Teams
Attendees: Lou Dunsmure, Marisa Lanzman, Avril Tucker, Lisa Boateng, Conor Jamieson, Nirlep Agravedi, Delyth Ahearne, Preety Ramdut, Rakhee, Patel, Rakhi Aggarwal

Amira Guirguis, Jegak Seo, Rebecca Braybrooks

Apologies: Mark Gilchrist, Rachel Berry, Aaron Brady, Frances Garraghan, Zoe Kennerley, Blessing Ukoha-Kalu

1: Recognition

Title	Welcome
Description	Introductions and actions from last meeting Actions from 21.01.26: - LD to bring together a short task and finish group to support pulling together resources to signpost – ICB AMS resources from 07.10.25: - Webinar re: how to do research in infection Future meeting dates: - To advise on further date for 2026
Purpose	To welcome and cover off any outstanding actions
Outcomes	• *Group welcomed to the meeting* • *Chair introduced the agenda and plans for the meeting* • *Apologies were noted.*

2: Relevance

Title	AmEAG activities
Description	1. Updates from AmEAG members on projects (Chair + all) 2. Workplan for AmEAG 3. WAAW campaign

Outcomes	***Terms of reference for group*** The TOR for expert advisory groups will be reviewed as a whole by the executive team and AmEAG will be involved in the TOR review for the group. ***Updates from group members were heard and covered the following points:*** ***Marisa*** *–* • *UKCPA masterclasses underway; Delivering session as FIS; OPAL study trial progressing. Supporting UKHSA fluoroquinolone clinical scenario development.* ***Conor*** *–* • *Ongoing work across NHS England; involved in AMR leadership funding, digital optimisation, allergy related work and AMR-related programmes. WAAW co-signed letter will be issued again this year.* ***Lisa*** *–* • *IPC priority: MRSA targeted approach (decolonisation focus).* • *Supporting improvement initiatives. New cohort starting in September who have independent prescribing qualification. Developing guidance and ongoing in-house pharmacy training.* • *Engaged in Covid federation learning and best practice sharing.* • *Awaiting mentorship programme rollout.* • *Supporting nurse-led IV-to-oral switch initiatives.* • *Workforce development in ID, how can AMS be included alongside discussions on medical microbiology and ID services.* • *Engagement with Regional Infection Groups (RIGs) and consideration of support structures.* ***Nirlep*** *–* • *ICB funding approved; programme commencing in coming months.* • *Cambridge SPARCS AI apprenticeship starting July 2026.Focus on improving AMS data utilisation through AI (year-long programme).* • *Working with EOLAS platform (IV-to-oral switch toolkit).* • *Acting as Hospital-Acquired Pneumonia representative for RCPharm.* ***Delyth*** *–* • *Joint Chair, South West Pharmacy Group.* • *Outputs include point prevalence work.* • *Strong education focus (BSAC resources highlighted).* • *Exploring development of an education package.* • *Looking into workforce engagement, penicillin allergy delabelling and WAAW planning* ***Preety*** *–* • *Infection Prevention Society strategy development.* • *Aiming to strengthen pharmacy/AMS involvement.* • *Expanding engagement to community and prescribers.* ***Louise*** *–*

	• *Collaboration with DeI underway regarding development of a toolkit to support peer review of AMS and IPC services* • *BOB Thames Valley pilot comparative study due completion by Christmas.* ***Conor (Funding & Strategy)*** *–* • *AMR leadership funding across ICB/ICS focusing on infection patterns and prescribing.* • *Up to £55k funding available through to 2030; all clusters funded.* • *Frontline productivity programme funding pending Treasury approval (digital optimisation).* • *National funding bids submitted for EPMA systems.* ***Avril*** *–* • *Transition into new role as Lead Practitioner (Infection Control).* • *Focus areas: reducing PPI prescribing, C. difficile reduction, and DDD reduction.* *The workplan priorities were then discussed and the following points were mentioned:* ***Workplan, Strategic Priorities & Innovation Focus*** *Core Priorities* • *Develop independent prescriber competencies using a profession-agnostic approach.* • *Align with the NHS "3 shifts", with a strong emphasis on digital transformation.* • *Support Pharmacy First and pathfinder programmes by:* o *Strengthening links across settings.* o *Clarifying the pharmacy/AMS offer.* o *Exploring CPEAG's role in outreach and support.* • *Leverage the revalidation process as an opportunity to embed AMS-related prompts and behaviours.* • *Map and optimise existing resources for prescribers:* o *Avoid duplication ("don't reinvent the wheel").* o *Encourage cross-sector sharing and adoption of best practice.* o *Strengthen collaboration and alignment with RPS/RCPharm to ensure a unified voice.* ***Digital & Innovation*** • *Embed AMS within the digital agenda, including:* o *Technology reviews and system optimisation.* o *Exploration and responsible adoption of AI in AMS.* • *Assess the impact of AI on:* o *Patient data* o *Diagnostics* o *Clinical decision-making*

	• *Develop guidance on AI use ("digital do's and don'ts"):*
	  ○ *Highlight risks, limitations, and safe use.*
	  ○ *Support organisations navigating uncertainty where clear answers are lacking.*
	• *Collaborate on a UKCPA & RPS joint AMS e-learning programme:*
	  ○ *Focus on foundational AMS knowledge for junior workforce*
	
	Key Focus Areas for Development
	• *Penicillin allergy de-labelling:*
	  ○ *Improve clinical questioning and assessment processes.*
	  ○ *Expand training across healthcare settings.*
	  ○ *Enable system-wide support and implementation.*
	• *Ensure strong alignment with existing initiatives, while identifying and addressing gaps.*
	• *Continue building cross-sector collaboration to maximise impact and resource utilisation.*
	• *Progress planning for **World Antimicrobial Awareness Week (WAAW)** at the next meeting.*

Title	**Sustainability Agenda**
Description	Progress actions since last meeting Further actions that the group can take
Outcomes	*Now part of Infection Society Sustainability group. Purpose is to help to shape and influence practice by supporting teams to include sustainability considerations in decision making processes e.g.reduce glove use.* *AOB* - *keep the AmEAG email distribution list open to all.* - *Blog posts aren't found on AmEAG webpage – can we link to them?*

Title	**AmEAG and RCPharm**
Description	Updates from Science and Research Team and around RCPharm **RCPharm Annual Conference 2026** • Abstract submission deadline extended to **17 June 2026**. • Call for AmEAG members to support dissemination and encourage submissions relevant to antimicrobial stewardship, infection, AMR, medicines optimisation and pharmacy research. **Parliamentary and Policy Engagement**

	• Reflections from the recent **House of Commons AMR Parliamentary Roundtable (May 2026)**. • Discussion of key themes arising from policymakers, researchers and healthcare professionals. • Consideration of how pharmacy can further contribute to national AMR policy, implementation and advocacy activities.
Purpose	To hear updates from around RCPharm
Outcomes	• *Reflections from House of commons visit 5 principles discussed:* 1. *Embed AWaRe-aligned prescribing competencies into postgraduate revalidation* 2. *Integrate One Health stewardship into the next UK National Action Plan (NAP)* 3. *Build interoperable NHS digital infrastructure before scaling AI for antimicrobial stewardship* 4. *Protect and expand the UK antimicrobial subscription model internationally* 5. *Establish a permanent AMR Research, Policy and Practice Interface* • *Abstract details shared.* • *Question on categories for submission*

RCPharm AmEAG: https://www.rcpharm.org/information/antimicrobial-expert-advisory-group/
RCPharm Events: https://www.rcpharm.org/events/
RCPharm Consultations: https://www.rcpharm.org/information/consultation-responses/